LDS/Medical Tests/NRAS (Neuroblastoma RAS Viral Oncogene Homolog) Gene Mutation Analysis

NRAS (Neuroblastoma RAS Viral Oncogene Homolog) Gene Mutation Analysis

NRAS belongs to the RAS proto-oncogene family and codes for GDP/GTP-regulated proteins (G-proteins). These proteins are a part of the signal transduction pathway. Upon extracellular signaling, they activate biochemical pathways that regulate growth and survival features of the cell. NRAS mediators are stimulated by receptor tyrosine kinases and they transduce the signals to the nucleus through the mitogen-activated protein kinase (MAPK) signaling pathway. Activating NRAS mutations lead to continued nuclear signaling resulting in proliferation of malignant cells. Thus, in the presence of NRAS mutations, therapies targeted against the upstream tyrosine kinases would be ineffective; therefore, drugs targeting the downstream genes in the MAPK signaling pathway need to be considered.

Activating mutations in the RAS family members (HRAS, KRAS and NRAS) have been reported in certain solid tumors, myeloid leukemia and melanoma. A particular RAS gene is activated in certain tumors and is somewhat tumor-specific — KRAS being more frequent in lung, pancreatic and colon cancer; NRAS in myeloid neoplasms and cutaneous melanomas. NRAS mutations are found in 20-30% of melanomas and approximately 3% of colorectal cancers. The majority of the mutations involving NRAS occur in exon 1 (codons 12, 13) and exon 2 (codon 61).

  • Aid in diagnosis and management of colon cancer
  • Screening patients with colon cancer and melanoma for targeted therapies
  • NRAS mutation might assist in anti-EGFR therapy evaluation
  • In patients with melanoma, the presence of NRAS mutation indicates that drugs targeted against MAPK signalling pathway could be effective
  • Presence of NRAS mutation indicates that therapies targeting upstream tyrosine kinsases (EGFR) would be ineffective while those targeting downstream MAPK signalling pathway would be effective
  • Absence of NRAS mutation does not guarantee a positive response to anti-EGFR therapy
  • Presence of NRAS mutation does not guarantee a positive response to drugs targeting MAPK signalling pathway
  • Wild type refers to a NRAS without detectable mutations in the codons 12, 13 and 61. Any mutations in the aforementioned codons will be reported as mutant NRAS

Negative for mutations analyzed (No mutation detected)

Polymerase chain reaction (PCR) followed by pyrosequencing, Conventional sequencing, Next Generation Sequencing, PCR follow by Allele Specific Primer Extension (ASPE) on chip array or liquid bead array technology.

Formalin fixed paraffin embedded (FFPE) tissues

Transported at ambient temperature.

Stability

  • Fixed tissues are stable for longer time
KRAS mutation, BRAF mutation, APC gene testing, MUTYH gene testing, Microsatellite Instability (MSI), p53.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login